1 There were no ablation-related changes in mechanical or heat
2 not explained by changes in metabolic rate, nor CO(2) , and
there were no changes in the HVR in normoxic mice.
3 Among smokers,
there were no clear associations between any of the exposures
4 There were no clinically relevant treatment-related serious a
5 There were no correlations with LGI1/CASPR2-IgG1-4 subclasses
6 arly feasibility study of the BEC for intermediate-risk PE,
there were no deaths or device-related adverse events and a s
7 ntration as low as one nanomolar, and at this concentration
there were no detectable effects on cell proliferation or via
8 There were no differences between progression rates using aut
9 There were no differences between women who initiated IPT ant
10 There were no differences in 28- or 90-day mortality rates.
11 Among patients >=65 years old,
there were no differences in adjusted 1-year risks of adverse
12 There were no differences in gender, BMI, % body fat, visual
13 gic outcomes than patients with pulseless arrests, although
there were no differences in immediate event outcomes or intr
14 In Langendorff-perfused hearts,
there were no differences in mean action potential duration (
15 There were no differences in outcomes between standard dose o
16 clusters for 3 of 18 pseudoviruses examined (P < .05), but
there were no differences in overall NAb breadth (P = .62).
17 were greater in Taz(KD) than in wild-type (WT) hearts, but
there were no differences in oxidative phosphorylation coupli
18 There were no differences in patient demographics, IDH/MGMT m
19 Below 10 ug/ml,
there were no dose-dependent cellular ROS increases or effect
20 There were no drug-related serious adverse events and no trea
21 There were no group differences on subjective reports of bad
22 There were no intra-abdominal abscess in either groups.
23 At 10 years,
there were no measurable differences in outcomes between pati
24 ve subretinal inflammation in patients at the higher doses,
there were no notable safety concerns after subretinal delive
25 Further,
there were no ocular serious AEs (SAEs) and no cases of endop
26 There were no other statistically significant differences.
27 There were no overall differences between primary and seconda
28 There were no postoperative complications or failure to obser
29 There were no significant benefits of medication on likelihoo
30 There were no significant between-group differences in both w
31 There were no significant between-group differences in seriou
32 There were no significant changes about lung function test, s
33 Although
there were no significant changes in the recession depth betw
34 At 6 months,
there were no significant differences between the injection (
35 At both 6 and 12 months, however,
there were no significant differences for these variables and
36 There were no significant differences in any of the secondary
37 There were no significant differences in clinical outcomes be
38 There were no significant differences in health care use or m
39 There were no significant differences in leptin (-0.7 ng/mL;
40 There were no significant differences in measures of mitochon
41 There were no significant differences in peak heart rate resp
42 Overall,
there were no statistically significant benefits of any inter
43 However,
there were no statistically significant differences in handgr
44 There were no statistically significant improvements in insul
45 By a post hoc analysis,
there were no statistically significant increases from week 5
46 Though
there were no statistically significant increases in KS rates
47 There were no strong correlations between the pathophysiologi
48 There were no therapy effects on the second standardised co-p
49 Respiration acclimated to elevated temperatures, but
there were no treatment effects on the Q(10) of respiration (
50 There were no unexpected adverse events with (177)Lu-PSMA ret